MedPath

Exparel Injection for Postoperative Orbital Pain

Phase 4
Recruiting
Conditions
Pain, Postoperative
Interventions
Registration Number
NCT02381353
Lead Sponsor
Mayo Clinic
Brief Summary

After surgery to remove the eye, either by enucleation or evisceration, patients have variable levels of pain for several postoperative days. Some patients have almost no discomfort while others require significant amounts of oral narcotics and report pain of 10 out of 10 on a numerical rating scale. The current operative standard is to infiltrate the eye socket with 0.5% bupivacaine during surgery leading to several hours of postoperative analgesia. In 2011, Pacira Pharmaceuticals released a bupivacaine liposomal injectable suspension (Exparel, 1.3%) which offers sustained release of bupivacaine giving postoperative pain control for up to 72 hours. This medication has been used in numerous surgeries including inguinal hernia repair, hemorrhoidectomy, bunionectomy, breast reconstruction, and orthopedic surgery, and the literature reports improved pain control, decreased use of oral opioids, and increased patient satisfaction. There are no reports of the use of Exparel in the ophthalmic literature. The investigators propose a randomized, controlled trial to compare the postoperative pain control offered by sustained release bupivacaine to that offered by standard plain bupivacaine after enucleation or evisceration.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
88
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Plain bupivacaineBupivacaineIntraoperative injection of local anesthetic agent, standard of care
Exparel (sustained release bupivacaine)BupivacaineIntraoperative injection of local anesthetic agent, long acting agent
Primary Outcome Measures
NameTimeMethod
Postoperative orbital painDays 3 postoperatively

Pain on a scale of 0-10, assessed on day 3 post enucleation or evisceration

Secondary Outcome Measures
NameTimeMethod
Postoperative nausea and vomitingDays 3 postoperatively

Nausea and vomiting on a scale of 0-3, assessed on day 3 post enucleation or evisceration

Quantity of oral narcotics used for postoperative pain controlDays 3 postoperatively

Number of oral narcotic pills taken during postoperative days 0-3

Patient satisfactionDay 3 postoperatively

Overall satisfaction with postoperative recovery, assessed on a scale of 1-5

Postoperative complications6-8 weeks postoperatively

Assessment of any postsurgical complications completed at postoperative visit

Trial Locations

Locations (2)

Mayo Clinic in Rochester

🇺🇸

Rochester, Minnesota, United States

University of Michigan Kellogg Eye Institute

🇺🇸

Ann Arbor, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath